Developing universal AAV immuno-gene therapy for oncology
Cell & Gene Therapy Insights 2023; 9(7), 997–1002
Published: 23 August
Traditional limits to the application of AAV-driven gene therapy are increasingly being eliminated. David McCall, Senior Editor, BioInsights, speaks to Nicole Paulk, CEO & Founder of Siren Biotechnology, about her team’s work in creating both the world’s first AAV-based immunotherapy in the oncology space, and the first universal AAV gene therapy product that can be used to treat multiple indications.